文章摘要
卡培他滨在晚期胃癌一线化疗后维持治疗中的应用
Application of capecitabine in maintenance treatment of advanced gastric cancer after first-line chemotherapy
投稿时间:2021-03-25  修订日期:2021-03-25
DOI:
中文关键词: 卡培他滨  晚期胃癌  一线化疗  维持治疗  不良反应  肿瘤标志物
英文关键词: capecitabine  advanced gastric cancer  first-line chemotherapy  maintenance therapy  adverse reactions  tumor markers
基金项目:
作者单位邮编
王松铃 王松铃 鄄城县人民医院 274600
摘要点击次数: 11
全文下载次数: 0
中文摘要:
      【摘要】目的:探讨卡培他滨在晚期胃癌一线化疗后维持治疗中的应用。方法:选取我院2018年2月至2020年5月期间我院收治的100例晚期胃癌患者作为研究对象,根据数字表法随机分为对照组(n=50)和观察组(n=50),对照组患者行一线化疗后进行常规对症治疗,观察组行一线化疗后的维持治疗中给药卡培他滨,比较两组治疗前后肿瘤标志物水平、不良反应发生率及半年内生存率。结果:治疗前两组肿瘤标志物水平无明显差异(P>0.05),经治疗观察组肿瘤标志物水平相比对照组更低(P<0.05)。观察组患者不良反应发生率相比对照组更低,半年内生存率相比对照组更高(P<0.05)。结论:晚期胃癌一线化疗后维持治疗中应用卡培他滨能够有效提升患者短期生存率,降低不良反应风险,因此可在临床中进行推广应用。
英文摘要:
      【Abstract】Objective: To explore the application of capecitabine in the maintenance treatment of advanced gastric cancer after first-line chemotherapy. Methods: Select 100 patients with advanced gastric cancer admitted to our hospital from February 2018 to May 2020 as the research objects, and randomly divide them into a control group (n=50) and an observation group (n=50) according to the number table method The control group received first-line chemotherapy followed by conventional symptomatic treatment, and the observation group received capecitabine in maintenance treatment after first-line chemotherapy. The levels of tumor markers, incidence of adverse reactions and survival within six months were compared between the two groups before and after treatment. Results: There was no significant difference in the levels of tumor markers between the two groups before treatment (P>0.05). The levels of tumor markers in the observation group after treatment were lower than those in the control group (P<0.05). The incidence of adverse reactions in the observation group was lower than that of the control group, and the survival rate within six months was higher than that of the control group (P<0.05). Conclusion: The application of capecitabine in maintenance treatment after first-line chemotherapy for advanced gastric cancer can effectively improve the short-term survival rate of patients and reduce the risk of adverse reactions, so it can be promoted and applied in the clinic.
View Fulltext   查看/发表评论  下载PDF阅读器
关闭

扫码关注本刊微信公众号“健康动向”